Table 2:
Laboratory test results for patients who received placebo or G-CSF after myocardial infarction
| Variable | Time after treatment; data value, mean ± SD* | ||||
|---|---|---|---|---|---|
| Day 0 | Day 4 | 1 wk | 6 wk | 26 wk | |
| CD34+, cells/μL median (IQR) | |||||
| Placebo group | 3.0 (2.0–6.0) | 5.0 (3.2–6.0) | 2.0 (1.5–5.0) | NA | NA |
| G-CSF group | 4.0 (2.0–7.0) | 52.5 (25.0–84.0)† | 3.0 (2.0–5.0) | NA | NA |
| Hemoglobin, g/L | |||||
| Placebo group | 134.7 ± 15.1 | 134.2 ± 14.1 | 135.8 ± 11.0 | 138.9 ± 13.5 | 138.2 ± 15.9 |
| G-CSF group | 137.7 ± 13.6 | 136.2 ± 15.0 | 138.3 ± 12.7 | 139.0 ± 13.0 | 140.4 ± 10.4 |
| Platelets, × 109/L | |||||
| Placebo group | 253.9 ± 78.7 | 294.5 ± 82.4 | 334.7 ± 100.3 | 244.5 ± 55.0 | 242.8 ± 60.2 |
| G-CSF group | 249.6 ± 66.5 | 304.4 ± 59.8 | 240.8 ± 78.6† | 263.56 ± 60.4 | 253.7 ± 36.2 |
| Leukocytes, × 109/L | |||||
| Placebo group | 9.4 ± 2.8 | 9.2 ± 2.7 | 8.7 ± 2.3 | 7.5 ± 2.0 | 7.5 ± 1.4 |
| G-CSF group | 9.6 ± 2.3 | 49.8 ± 12.8† | 9.1 ± 3.3 | 7.7 ± 1.7 | 8.1 ± 2.3 |
| Lymphocytes, × 109/L | |||||
| Placebo group | 2.0 ± 0.6 | 2.1 ± 0.6 | 1.9 ± 0.5 | 1.9 ± 0.6 | 2.0 ± 0.6 |
| G-CSF group | 2.4 ± 0.8 | 5.0 ± 2.6† | 2.2 ± 0.7 | 2.3 ± 0.7 | 2.5 ± 0.8 |
| Monocytes, × 109/L | |||||
| Placebo group | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.3 | 0.5 ± 0.2 | 0.4 ± 0.1 |
| G-CSF group | 0.7 ± 0.3 | 2.5 ± 1.5† | 0.4 ± 0.2 | 0.5 ± 0.1 | 0.5 ± 0.2 |
| Neutrophils, × 109/L | |||||
| Placebo group | 6.5 ± 2.3 | 6.2 ± 2.3 | 6.0 ± 2.0 | 4.8 ± 1.5 | 4.5 ± 1.2 |
| G-CSF group | 6.2 ± 2.1 | 37.7 ± 10.0† | 5.7 ± 2.2 | 4.6 ± 1.2 | 4.7 ± 1.7 |
Note: G-CSF = granulocyte colony-stimulating factor, IQR = interquartile range, NA = not applicable, SD = standard deviation.
*
Unless otherwise stated.
†
p < 0.05.